Pathologic report of prostate biopsy | Odds ratio | 95% CI | P value | ||
---|---|---|---|---|---|
Non-Prostate Ca. (n = 152) | Prostate Ca. (n = 152) | ||||
Age (years)a | 67.8 ± 6.4 | 67.9 ± 7.0 | 0.986 | ||
Diabetes mellitusb | 1.15 | 0.84–1.58 | 0.761 | ||
No | 125 (82.2%) | 127 (83.6%) | |||
Yes | 27 (17.8%) | 25 (16.4%) | |||
Hypertensionb | 1.22 | 0.96–1.56 | 0.422 | ||
No | 72 (47.4%) | 79 (52.0%) | |||
Yes | 80 (52.6%) | 73 (48.0%) | |||
Hemoglobin (g/dL)a | 14.5 ± 1.2 | 14.4 ± 1.2 | 0.902 | ||
Alkaline phosphatase (U/L)a | 68.5 ± 17.5 | 69.5 ± 18.3 | 0.669 | ||
Albumin (g/dL)a | 4.2 ± 0.3 | 4.2 ± 0.3 | 0.670 | ||
PSA (ng/mL)a | 6.8 ± 1.6 | 7.0 ± 1.6 | 0.077 | ||
RETzPSA (ng/mL) a | 3.99 ± 1.16 | 4.78 ± 1.33 | < 0.001 | ||
EPHPSA (ng/mL)a | 0.95 ± 0.12 | 1.00 ± 0.10 | 0.001 | ||
Prostate vol.(cc)a | 45.0 ± 16.8 | 33.7 ± 14.5 | < 0.001 | ||
Prostate transitional vol.(cc)a | 18.1 ± 11.7 | 11.4 ± 8.7 | < 0.001 | ||
PSAD (ng/mL/cc)a | 0.17 ± 0.07 | 0.24 ± 0.10 | < 0.001 | ||
PZPSAD (ng/mL/cc)a | 0.27 ± 0.10 | 0.35 ± 0.14 | < 0.001 | ||
ETzD (ng/mL/cc)a | 0.038 ± 0.01 | 0.049 ± 0.01 | < 0.001 | ||
DRE hardnessb | 1.99 | 1.21–3.27 | 0.006 | ||
No | 116 (76.3%) | 94 (61.8%) | |||
Yes | 36 (23.7%) | 58 (38.2%) | |||
DRE tendernessb | 2.04 | 0.50–8.32 | 0.310 | ||
No | 149 (98.0%) | 146 (96.1%) | |||
Yes | 3 (2.0%) | 6 (3.9%) | |||
TRUS hypoechoic lesionb | 2.86 | 1.65–4.94 | < 0.001 | ||
No | 128 (84.2%) | 99 (65.1%) | |||
Yes | 24 (15.8%) | 53 (34.9%) | |||
TRUS calcification lesionb | 0.54 | 0.34–0.86 | 0.010 | ||
No | 82 (53.9%) | 104 (68.4%) | |||
Yes | 70 (46.1%) | 48 (31.6%) | |||
TRUS cystic lesionb | 0.60 | 0.29–1.22 | 0.156 | ||
No | 130 (85.5%) | 138 (90.8%) | |||
Yes | 22 (14.5%) | 14 (9.2%) |